Halozyme and Skye Collaborate on Nimacimab for Obesity Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy HALO?
Source: PRnewswire
Halozyme Therapeutics Inc (HALO) saw a price increase of 3.30%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 0.88% and the S&P 500 up 0.63%.
This surge is attributed to the collaboration agreement between Halozyme and Skye Bioscience, allowing Skye to license Halozyme's ENHANZE® drug delivery technology for developing a subcutaneous formulation of nimacimab. This partnership is expected to enhance treatment potential in the obesity market and includes plans for a Phase 2b clinical trial to assess the drug's efficacy.
The collaboration not only strengthens Halozyme's competitive position in the biopharmaceutical sector but also promises sustainable revenue growth through mid-single digit royalties from Skye's sales, reinforcing investor confidence in the company's future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78.00 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 78.420
Low
56.00
Averages
78.00
High
92.00
Current: 78.420
Low
56.00
Averages
78.00
High
92.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tech Stocks Struggle While Consumer Staples Shine
- Tech Sector Weakness: On Tuesday, tech stocks like AMD and Lumentum struggled, leading to a bearish market sentiment that reflects investor concerns over high valuations, potentially impacting future investment decisions.
- Consumer Staples Resilience: In stark contrast to tech stocks, the consumer staples sector showed strong performance, indicating a market preference for stable earnings, which may attract more capital into this area to mitigate risk.
- Regional Banks' Steady Growth: Regional banks demonstrated resilience amid market volatility, drawing investor attention and suggesting that traditional financial institutions remain attractive in uncertain economic conditions, potentially driving their stock prices higher.
- Precious Metals and Industrials Recovery: The strong performance of precious metals and industrials indicates an increased demand for safe-haven assets, reflecting investor concerns about potential economic slowdowns, which could influence investment strategies in related sectors.
See More
Halozyme Raises 2026 Revenue Guidance and Acquires Surf Bio
- Revenue Guidance Increase: Halozyme raised its 2026 revenue guidance to $1.71 to $1.81 billion, reflecting a growth of 23% to 30%, surpassing the analyst estimate of $1.69 billion, indicating strong market performance and growth potential.
- Earnings Per Share Forecast Boost: The company now expects adjusted earnings per share of $7.75 to $8.25 for 2026, up from the previous estimate of $6.50 to $7.00, showcasing enhanced profitability and increased market confidence.
- Surf Bio Acquisition: Halozyme announced the acquisition of Surf Bio for up to $400 million, which includes an upfront payment of $300 million and milestone payments of up to $100 million, aimed at expanding its drug delivery opportunities and strengthening its competitive position.
- Positive Stock Market Reaction: Following the announcement of its preliminary 2025 estimates, Halozyme's shares rallied 3%, and the stock has risen 29% over the past 12 months, reflecting growing investor confidence in the company's future prospects.
See More
Halozyme Raises 2026 Financial Guidance Amid Strong Growth
- Guidance Upgrade: Halozyme raised its 2026 total revenue guidance from $1.43-$1.53 billion to $1.71-$1.81 billion, anticipating a year-over-year growth rate of 23%-30%, highlighting the company's robust long-term growth potential.
- Strong Sales Outlook: The company projects fiscal 2025 sales between $1.385 billion and $1.4 billion, reflecting a year-over-year increase of 36%-38%, with royalty revenues expected to be $865 million to $870 million, further solidifying its market position.
- EBITDA Expectations: Halozyme forecasts adjusted EBITDA for 2026 to range from $1.125 billion to $1.205 billion, indicating a proactive investment strategy, particularly with approximately $60 million tied to Hypercon and Surf Bio.
- Acquisition-Driven Growth: The company acquired Surf Bio for $300 million upfront, with potential additional milestone payments of up to $100 million, which will enhance its product portfolio and drive future revenue growth.
See More
Halozyme Raises Financial Outlook and Acquires Surf Bio for Up to $400M
- Financial Outlook Upgrade: Halozyme raised its 2025 total revenue forecast to $1.385B-$1.4B, exceeding the consensus estimate of $1.34B by $45M-$60M, indicating strong growth potential with an expected year-over-year increase of 36%-38%.
- Acquisition of Surf Bio: The company announced the acquisition of biopharmaceutical firm Surf Bio for up to $400M, with $300M upfront and up to $100M in milestone payments, enhancing its technological capabilities in the biopharmaceutical sector.
- EPS Guidance Increase: Halozyme raised its non-GAAP diluted EPS outlook from $6.50-$7.00 to $7.75-$8.25, surpassing the market estimate of $8.21, reflecting the positive impact of new investments, particularly the $60M in Hypercon and Surf Bio.
- Technological Innovation: Surf Bio's biologic hyperconcentration technology enables concentrations of up to 500 mg/mL for various therapeutics, including monoclonal antibodies and small molecules, which is expected to promote the adoption of auto-injector delivery methods for at-home or healthcare provider use.
See More
Halozyme Raises 2026 Financial Guidance and Acquires Surf Bio
- 2025 Revenue Estimates: Halozyme anticipates total revenue for 2025 to reach between $1.385 billion and $1.4 billion, reflecting a year-over-year growth of 36% to 38%, which underscores the robust momentum of its core business in the biopharmaceutical sector.
- 2026 Financial Outlook: The company has raised its 2026 total revenue guidance to between $1.71 billion and $1.81 billion, with expected year-over-year growth of 23% to 30%, while projecting royalty revenue to exceed $1 billion, growing at 30% to 35%, indicating sustained market demand and a strong business model.
- Acquisition of Surf Bio: Halozyme acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments up to $400 million, aimed at leveraging its innovative hyperconcentration technology to enhance the delivery of antibodies and biologics, thereby expanding its drug delivery portfolio.
- Strategic Partnership Expansion: In 2025, Halozyme signed three new ENHANZE collaboration agreements and multiple auto-injector development agreements, further strengthening its competitive position in drug delivery and laying the groundwork for future revenue growth.
See More
Halozyme Updates Preliminary 2025 Financial Estimates and Raises 2026 Guidance
- 2025 Revenue Estimates: Halozyme anticipates total revenue of $1.385 to $1.4 billion for 2025, reflecting a year-over-year growth of 36% to 38%, indicating strong growth potential in its core business, particularly driven by sustained demand for patented products.
- 2026 Guidance Increase: The company raised its 2026 total revenue forecast to $1.71 to $1.81 billion, projecting a year-over-year growth of 23% to 30%, which underscores the robust growth of its royalty revenue expected to exceed $1 billion, growing by 30% to 35%.
- Acquisition of Surf Bio: Halozyme acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments of up to $100 million, aiming to leverage its hyperconcentration technology to enhance the delivery efficiency of antibodies and biologics, thereby expanding its drug delivery market.
- New Collaboration Agreements: In 2025, Halozyme signed three new ENHANZE collaboration agreements along with multiple auto-injector commercial licensing agreements, demonstrating its strategic expansion and enhanced market penetration capabilities in the drug delivery sector.
See More
Tech Stocks Struggle While Consumer Staples Shine
- Tech Sector Weakness: On Tuesday, tech stocks like AMD and Lumentum struggled, leading to a bearish market sentiment that reflects investor concerns over high valuations, potentially impacting future investment decisions.
- Consumer Staples Resilience: In stark contrast to tech stocks, the consumer staples sector showed strong performance, indicating a market preference for stable earnings, which may attract more capital into this area to mitigate risk.
- Regional Banks' Steady Growth: Regional banks demonstrated resilience amid market volatility, drawing investor attention and suggesting that traditional financial institutions remain attractive in uncertain economic conditions, potentially driving their stock prices higher.
- Precious Metals and Industrials Recovery: The strong performance of precious metals and industrials indicates an increased demand for safe-haven assets, reflecting investor concerns about potential economic slowdowns, which could influence investment strategies in related sectors.
See More
Halozyme Raises 2026 Revenue Guidance and Acquires Surf Bio
- Revenue Guidance Increase: Halozyme raised its 2026 revenue guidance to $1.71 to $1.81 billion, reflecting a growth of 23% to 30%, surpassing the analyst estimate of $1.69 billion, indicating strong market performance and growth potential.
- Earnings Per Share Forecast Boost: The company now expects adjusted earnings per share of $7.75 to $8.25 for 2026, up from the previous estimate of $6.50 to $7.00, showcasing enhanced profitability and increased market confidence.
- Surf Bio Acquisition: Halozyme announced the acquisition of Surf Bio for up to $400 million, which includes an upfront payment of $300 million and milestone payments of up to $100 million, aimed at expanding its drug delivery opportunities and strengthening its competitive position.
- Positive Stock Market Reaction: Following the announcement of its preliminary 2025 estimates, Halozyme's shares rallied 3%, and the stock has risen 29% over the past 12 months, reflecting growing investor confidence in the company's future prospects.
See More
Halozyme Raises 2026 Financial Guidance Amid Strong Growth
- Guidance Upgrade: Halozyme raised its 2026 total revenue guidance from $1.43-$1.53 billion to $1.71-$1.81 billion, anticipating a year-over-year growth rate of 23%-30%, highlighting the company's robust long-term growth potential.
- Strong Sales Outlook: The company projects fiscal 2025 sales between $1.385 billion and $1.4 billion, reflecting a year-over-year increase of 36%-38%, with royalty revenues expected to be $865 million to $870 million, further solidifying its market position.
- EBITDA Expectations: Halozyme forecasts adjusted EBITDA for 2026 to range from $1.125 billion to $1.205 billion, indicating a proactive investment strategy, particularly with approximately $60 million tied to Hypercon and Surf Bio.
- Acquisition-Driven Growth: The company acquired Surf Bio for $300 million upfront, with potential additional milestone payments of up to $100 million, which will enhance its product portfolio and drive future revenue growth.
See More
Halozyme Raises Financial Outlook and Acquires Surf Bio for Up to $400M
- Financial Outlook Upgrade: Halozyme raised its 2025 total revenue forecast to $1.385B-$1.4B, exceeding the consensus estimate of $1.34B by $45M-$60M, indicating strong growth potential with an expected year-over-year increase of 36%-38%.
- Acquisition of Surf Bio: The company announced the acquisition of biopharmaceutical firm Surf Bio for up to $400M, with $300M upfront and up to $100M in milestone payments, enhancing its technological capabilities in the biopharmaceutical sector.
- EPS Guidance Increase: Halozyme raised its non-GAAP diluted EPS outlook from $6.50-$7.00 to $7.75-$8.25, surpassing the market estimate of $8.21, reflecting the positive impact of new investments, particularly the $60M in Hypercon and Surf Bio.
- Technological Innovation: Surf Bio's biologic hyperconcentration technology enables concentrations of up to 500 mg/mL for various therapeutics, including monoclonal antibodies and small molecules, which is expected to promote the adoption of auto-injector delivery methods for at-home or healthcare provider use.
See More
Halozyme Raises 2026 Financial Guidance and Acquires Surf Bio
- 2025 Revenue Estimates: Halozyme anticipates total revenue for 2025 to reach between $1.385 billion and $1.4 billion, reflecting a year-over-year growth of 36% to 38%, which underscores the robust momentum of its core business in the biopharmaceutical sector.
- 2026 Financial Outlook: The company has raised its 2026 total revenue guidance to between $1.71 billion and $1.81 billion, with expected year-over-year growth of 23% to 30%, while projecting royalty revenue to exceed $1 billion, growing at 30% to 35%, indicating sustained market demand and a strong business model.
- Acquisition of Surf Bio: Halozyme acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments up to $400 million, aimed at leveraging its innovative hyperconcentration technology to enhance the delivery of antibodies and biologics, thereby expanding its drug delivery portfolio.
- Strategic Partnership Expansion: In 2025, Halozyme signed three new ENHANZE collaboration agreements and multiple auto-injector development agreements, further strengthening its competitive position in drug delivery and laying the groundwork for future revenue growth.
See More
Halozyme Updates Preliminary 2025 Financial Estimates and Raises 2026 Guidance
- 2025 Revenue Estimates: Halozyme anticipates total revenue of $1.385 to $1.4 billion for 2025, reflecting a year-over-year growth of 36% to 38%, indicating strong growth potential in its core business, particularly driven by sustained demand for patented products.
- 2026 Guidance Increase: The company raised its 2026 total revenue forecast to $1.71 to $1.81 billion, projecting a year-over-year growth of 23% to 30%, which underscores the robust growth of its royalty revenue expected to exceed $1 billion, growing by 30% to 35%.
- Acquisition of Surf Bio: Halozyme acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments of up to $100 million, aiming to leverage its hyperconcentration technology to enhance the delivery efficiency of antibodies and biologics, thereby expanding its drug delivery market.
- New Collaboration Agreements: In 2025, Halozyme signed three new ENHANZE collaboration agreements along with multiple auto-injector commercial licensing agreements, demonstrating its strategic expansion and enhanced market penetration capabilities in the drug delivery sector.
See More
